With the discovery of the oncogenic function of EGFR, TKIs have dramatically changed the treatment landscape of advanced NSCLC from conventional cytotoxic chemotherapy to targeted therapy in recent years. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.